Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZEPHYR: GBT440 for Hypoxemia in Idiopathic Pulmonary Fibrosis Using Supplemental Oxygen at Rest
2017-001276-27Phase 2Terminated
- Sponsor
- Global Blood Therapeutics
- Start
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of voxelotor in idiopathic pulmonary fibrosis (IPF), sponsored by Global Blood Therapeutics. Primary endpoint: Change in oxygen saturation at rest on room air. Started May 2017; status: terminated.
02
Drugs
voxelotor
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on 2017-001276-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001276-27.